Company research
ASCENTAGE PHARMA GROUP INTERNATIONAL
CIK 2023311Updated Sep 26, 2026
SecurityAAPG · NASDAQ · adr
AAPG price & chart
Loading TradingView…
NASDAQ:AAPG on TradingView ↗About the company
We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets and significant unmet global medical needs. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, or CML, acute myeloid leukemia, or AML, chronic lymphocytic leukemia, or CLL, acute lymphocytic leukemia, or ALL, myelodysplastic syndrome, or MDS, and multiple myeloma, or MM, which is expected to exceed US$166 billion in aggregate market size by 2035, according to the industry report commissioned by us and independently prepared by Frost & Sullivan in connection with this offering, or the F&S Report. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators, according to the F&S Report. We have eleven completed or ongoing U.S. and/or internatio…
In the news
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossUSD | -55,577,000Source | -925,712,000Source |
| Additional Financial Items | ||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 8,597,000Source | -91,537,000Source |
| AdjustmentsForFinanceCostsUSD | 8,830,000Source | 96,057,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesUSD | -38,000Source | 1,076,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 2,867,000Source | 31,503,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -917,000Source | -1,621,000Source |
| GoodwillUSD | 3,383,000Source | 24,694,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 8,296,000Source | 92,348,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,153,000Source | 10,766,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesCNY | — | 5,923,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 73,421,000Source | 953,500,000Source |
| ProceedsFromIssuingSharesUSD | 73,149,000Source | 470,081,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCNY | — | 14,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesCNY | — | 10,736,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 92,180,000Source | 956,091,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| Cost of Goods and Services Sold | — | — |
| Total RevenueUSD | 134,348,000Source | 221,984,000Source |
| Additional Financial Items | ||
| AdministrativeExpenseUSD | 25,636,000Source | 181,076,000Source |
| BasicEarningsLossPerShareUSD per share | -0.18Source | -3.28Source |
| DeferredTaxExpenseIncomeUSD | 1,428,000Source | -7,150,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCNY | -3,881,000Source | -1,517,000Source |
| DepreciationRightofuseAssetsUSD | 1,525,000Source | 1,594,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.18Source | -3.28Source |
| DonationsAndSubsidiesExpenseUSD | 866,000Source | 3,988,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedUSD | 33,000Source | 181,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesUSD | 33,000Source | 181,000Source |
| FinanceCostsUSD | 8,830,000Source | 96,057,000Source |
| GrossProfitUSD | 130,364,000Source | 191,441,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 1,428,000Source | -7,150,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 205,000Source | 1,321,000Source |
| OtherIncomeUSD | 7,858,000Source | 59,316,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 4,713,000Source | 30,705,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -34,000Source | -75,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -55,543,000Source | -925,637,000Source |
| ProfitLossBeforeTaxUSD | -54,149,000Source | -932,862,000Source |
| ResearchAndDevelopmentExpenseUSD | 129,772,000Source | 706,972,000Source |
| SellingExpenseUSD | 26,852,000Source | 195,387,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -38,000Source | -38,000Source |
Offerings
Registration 333-284064
- Gross proceeds
- 126356250.0
- Net proceeds
- 117511312.0
- Deal price
- 17.25
- Shares
- 7325000
- Offering price
- $17.25
- Ticker
- AAPG